UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                 Amendment No. 2
                                       to
                                    Form 10-K

                ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

                      For fiscal year ended March 31, 2015

                        Commission File Number 000-55023

                                   ZLATO INC.
             (Exact name of registrant as specified in its Charter)

           Nevada                                                46-3883208
(State or other jurisdiction of                               (I.R.S. Employer
 incorporation or organization)                              Identification No.)

                   Mlynska 28, 040 01 Kosice, Slovak Republic
               (Address of principal executive offices) (Zip Code)

                                  646-875-5747
              (Registrant's telephone number, including area code)

                                 Not Applicable
              (Former name, former address, and former fiscal year,
                          if changed since last report)

           Securities registered pursuant to Section 12(b) of the Act:
                                      None

           Securities registered pursuant to Section 12(g) of the Act:
                         Common Stock, par value $0.001
                                (Title of class)

Indicate by check mark if the  registrant is a well-known  seasoned  issuer,  as
defined in Rule 405 of the Securities Act. Yes [ ] No [X]

Indicate  by  check  mark if the  registrant  is not  required  to file  reports
pursuant to Section 13 or Section 15(d) of the Act. Yes [ ] No [X]

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the  preceding 12 months (or for such  shorter  period that the  registrant  was
required  to file  such  reports),  and  (2) has  been  subject  to such  filing
requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted  electronically  and
posted on its corporate Web site, if any, every  Interactive  Data File required
to be submitted and posted  pursuant to Rule 405 of Regulation S-T (ss.  232.405
of this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit and post such files). Yes [X ] No [ ]

Indicate by check mark if disclosure of delinquent  filers  pursuant to Item 405
of Regulation  S-K is not contained  herein,  and will not be contained,  to the
best of registrant's  knowledge,  in definitive proxy or information  statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. [ ]

Indicate by check mark whether the registrant is a large  accelerated  filer, an
accelerated  filer or a  non-accelerated  filer.  See definition of "accelerated
filer and large  accelerated  filer" in Rule 12b-2 of the Exchange  Act.  (Check
one):

Large accelerated filer [ ]                        Accelerated filer [ ]
Non-accelerated filer [ ]                          Smaller reporting company [X]

Indicate by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act). Yes [X] No [ ]

At September 30, 2014, the last business day of the  Registrant's  most recently
completed second fiscal quarter, the aggregate market value of the voting common
stock held by  non-affiliates  of the  Registrant  (without  admitting  that any
person whose shares are not included in such  calculation  is an affiliate)  was
$50,000.  At March 31, 2015, the end of the Registrant's most recently completed
fiscal year, there were 6,000,000  shares of the Registrant's  common stock, par
value $0.001 per share, outstanding.

                                EXPLANATORY NOTE

This Amendment No. 2 on Form 10-K (this "Amendment") to Zlato Inc.'s Annual
Report on Form 10-K for the fiscal year ended March 31, 2015, originally filed
with the Securities and Exchange Commission on June 12, 2015 (the "Original
Filing"), is being filed for the purpose of correcting an incorrect reference to
our disclosure controls and procedures being effective as of March 31, 2015 in
Part II, Item 9A. Controls and Procedures, "Disclosure Controls and Procedures,"
of the Original Filing. Except as described above, no other changes have been
made to the Original Filing and Amendment No. 1 to Form 10-K ("Amendment No.
1"), filed on December 22, 2015. This Amendment does not modify, amend, or
update in any way any of the financial or other information contained in the
Original Filing and Amendment No. 1. This Amendment does not reflect events that
may have occurred subsequent to the filing dates of the Original Filing.
<PAGE>
                         ZLATO INC. - TABLE OF CONTENTS

          PART I

ITEM 1.   Business                                                            2
ITEM 1A.  Risk Factors                                                        9
ITEM 1B.  Unresolved Staff Comments                                          10
ITEM 2.   Properties                                                         10
ITEM 3.   Legal Proceedings                                                  10
ITEM 4.   Mine Safety Disclosures                                            10

          PART II

ITEM 5.   Market for Registrant's Common Equity, Related Stockholder
          Matters and Issuer Purchases of Equity Securities                  10
ITEM 6.   Selected Financial Data                                            11
ITEM 7.   Management's Discussion and Analysis of Financial Condition
          and Results of Operations                                          11
ITEM 7A.  Quantitative and Qualitative Disclosures About Market Risk         14
ITEM 8.   Financial Statements and Supplementary Data                        15
ITEM 9.   Changes In and Disagreements with Accountants on Accounting
          and Financial Disclosure                                           26
ITEM 9A.  Controls and Procedures                                            26
ITEM 9B.  Other Information                                                  27

          PART III

ITEM 10.  Directors, Executive Officers, and Corporate Governance            27
ITEM 11.  Executive Compensation                                             29
ITEM 12.  Security Ownership of Certain Beneficial Owners and Management
          and Related Stockholder Matters                                    30
ITEM 13.  Certain Relationships and Related Transactions, and Director
          Independence                                                       31
ITEM 14.  Principal Accounting Fees and Services                             31

          PART IV

ITEM 15.  Exhibits, Financial Statement Schedules                            32

          Signatures                                                         33
<PAGE>
              CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This  Annual  Report  on Form  10-K of Zlato  Inc.,  a Nevada  corporation  (the
"Company"),  contains  "forward-looking  statements,"  as  defined in the United
States Private Securities  Litigation Reform Act of 1995. In some cases, you can
identify  forward-looking  statements  by  terminology  such as  "may",  "will",
"should", "could", "expects",  "plans",  "intends",  "anticipates",  "believes",
"estimates", "predicts", "potential" or "continue" or the negative of such terms
and other comparable  terminology.  These  forward-looking  statements  include,
without  limitation,  statements about our market  opportunity,  our strategies,
competition,  expected  activities  and  expenditures  as we pursue our business
plan, and the adequacy of our available cash resources. Although we believe that
the expectations reflected in the forward-looking  statements are reasonable, we
cannot   guarantee   future   results,   levels  of  activity,   performance  or
achievements.   Actual  results  may  differ  materially  from  the  predictions
discussed in these forward-looking  statements.  The economic environment within
which we operate could materially affect our actual results.  Additional factors
that could materially affect these forward-looking statements and/or predictions
include,  among  other  things:  the  Company's  need for and  ability to obtain
additional financing,  the volatility of real estate prices, and the exercise of
the control by Dana Gallovicova,  the Company's sole officer and director, other
factors over which we have little or no control;  and other factors discussed in
the Company's filings with the Securities and Exchange Commission ("SEC").

Our management has included  projections and estimates in this Form 10-K,  which
are based primarily on management's  experience in the industry,  assessments of
our results of operations, discussions and negotiations with third parties and a
review  of  information  filed  by our  competitors  with  the SEC or  otherwise
publicly  available.  We caution readers not to place undue reliance on any such
forward-looking  statements,  which speak only as of the date made.  We disclaim
any obligation subsequently to revise any forward-looking  statements to reflect
events or  circumstances  after the date of such  statements  or to reflect  the
occurrence of anticipated or unanticipated events.

                                  INTRODUCTION

Unless  otherwise  specified  or  required  by  context,  as used in this Annual
Report,  the terms "we," "our," "us" and the  "Company"  refer  collectively  to
Zlato Inc.  The term  "fiscal  year"  refers to our fiscal year ending March 31.
Unless  otherwise  indicated,  the term "common  stock"  refers to shares of our
common stock.

Our  financial  statements  are stated in United  States  Dollars  (US$) and are
prepared  in  accordance  with  United  States  generally  accepted   accounting
principles (U.S. GAAP).

                                       1
<PAGE>
                                     PART I

ITEM 1. BUSINESS

We were  incorporated  on February  25, 2013 in the State of Nevada to engage in
the development and sale of electronic medical record ("EMR") software for small
and medium sized physician offices and clinics.  Our principal executive offices
are located at Mlynska 28, 040 01 Kosice,  Slovak Republic.  Our phone number is
(646) 875-5747. We currently have no revenues, and we have no subsidiaries.  Our
trading symbol on OTC Markets is "ZFLO".

We have never declared  bankruptcy,  have never been in  receivership,  and have
never been involved in any legal action or proceedings. Since incorporation,  we
have not made any  significant  purchase  or sale of assets.  We are not a blank
check  registrant  as that term is defined in Rule  419(a)(2) of Regulation C of
the Securities Act of 1933,  since we have a specific  business plan or purpose.
We do not have any present plans or arrangements with any representatives of the
owners of any business or company regarding the possibility of an acquisition or
merger.

PRINCIPAL PRODUCTS AND SERVICES

We completed a registered  offering and raised $50,000 in 2014, which we used to
complete  development  of our  basic  EMR  software  and for the  launch  of our
website.  You can view the website and register to view and use our EMR software
at www.zlatoinc.com.

Our basic EMR software  collects and captures patient data  electronically,  and
stores  it  in  a  format  that  enables  efficient  access  and  viewing,   and
distribution by printing or email. Our planned second phase product  development
will focus on  interconnectivity  of our EMR software  with various  third party
vital signs monitors, such as blood pressure monitors or temperature monitors.

We currently have no revenues,  no operating  history,  and no users or revenues
for our  software.  We need to raise an  additional  $200,000  to  maintain  our
existence and fund an adequate marketing program to launch our product.  We need
another  $50,000 to further  develop our  software  over an 8-10 month period to
interface  with  third  party  diagnostic  and  vital  signs  monitor  equipment
suppliers.

We cannot  guarantee we will be successful  with planned our business  plan. Our
business is subject to all of the risks inherent in the  establishment  of a new
business  enterprise.  We  currently  have no funds,  and our  Director has been
lending our company funds only to pay for our  corporate  existence and maintain
our  regulatory  filings.  We will not be able to  commercially  launch  our EMR
product without additional  financing.  Without additional financing on a timely
basis, our business will fail.

PRINCIPAL PRODUCTS AND SERVICES

An Electronic Medical Record ("EMR") is the digital or software based version of
a paper-based  medical  record,  which is generated by the patient's  healthcare
provider for each patient  encounter or visit. EMRs contain the data captured or
transcribed  in electronic  format from all medical  departments  related to the
particular visit, such as laboratory or blood work, pharmacy  prescriptions,  or
x-ray or other forms of radiology or body scanning. Digital EMRs are stored on a

                                       2
<PAGE>

computer  database,  either  onsite or offsite,  and the software is designed to
provide a structured and integrated  method of gathering,  storing,  retrieving,
and  sharing of a  particular  patient's  healthcare  record.  This  compares to
traditional  paper  based  records,  which  are  written  by hand and  stored in
physical paper files in the health care providers' physical office.

EMR solutions  help to achieve  paperless  administration  across the healthcare
industry. This form of administration will ultimately facilitate the creation of
a centralized  patient  repository.  The records  generated  through  successful
implementation of EMRs in healthcare  practices can be used for various purposes
such as patient care, administration,  research, healthcare quality improvement,
and  processing  of  reimbursements.  EMR is a part  of  healthcare  information
technology that is used to make paperless  computerized patient data in order to
increase efficiency of primary care facilities.

In the USA and most other  developed  countries  that have either  privately  or
publically  funded  healthcare,  paper  based and EMR  software  and records are
maintained  and controlled by the healthcare  provider  organization  (hospital,
clinic or physician).  We believe our product can potentially provide a superior
solution  to  reduce  the time and  cost to  record  patient  data  through  the
standardization  of data entry,  enable more comprehensive real time data entry,
and enable the smaller and medium sized  offices to better  manage their patient
records, all of which can potentially reduce record errors.

Our basic EMR software has been developed to provide on line, real time computer
access and contains an easy to use physician/medical personnel interface, and an
electronic  database backend which collects and organizes all patient data in an
efficient,  error free, and secure,  and private manner. If we are successful in
raising  suitable  financing  to launch our  product,  we plan to modify the EMR
software  to satisfy  all  mandatory  regulatory  and  compliance  issues in the
countries  where we ultimately  offer the product,  and ensure that it qualifies
for any available EMR incentive funding available from government agencies.  Our
software  was  designed  with open  architecture,  therefore  allowing  changes,
additions,  modifications  of EMR components with ease. This flexibility is also
important for connectivity  with multiple device  manufacturers,  as each device
will  require  its unique  components  to  interface  with our system to capture
patient data without the need for human interface.

Our planned  distribution and revenue models may undergo significant  revisions,
as we get  closer to  launching  our  commercial  product.  At this stage in our
development,  there can be no assurance that we will be successful in generating
revenues  from our  product,  or that users will be  receptive to even using the
product.

THE MARKET

We consider  our  proposed  business to be a segment of the overall  health care
industry.  We are planning to target small to medium sized physician offices and
clinics in the USA,  providing we are successful in raising  sufficient funds to
commercialize  our  product.  According to the most recent  Federation  of State
Medical Boards census released just several weeks ago, there were  approximately
912,000  physicians  in the  USA in  2014  and  although  there  are no  current
definitive   government   statistics,   various   private   surveys  of  medical
professionals  generally indicate that a significant majority were practicing in
groups of 9 or less. We are also planning to focus on the USA because the USA is
primarily a private,  for profit system under which  physicians have significant
autonomy over equipping their practices and related infrastructure.

                                       3
<PAGE>
Two primary  factors are driving the conversion to EMR from paper based records.
First,  is the rising demand for the  healthcare  cost  containment  and need to
improve the quality of healthcare  services.  EMR solutions will help to improve
clinical efficiency in the following ways:

     *    Provide improved accessibility to patient records
     *    Improved  communication between provider and clinical departments such
          as pharmacy, laboratory, and other clinical departments
     *    Improved communication among healthcare facilities
     *    Reduced  transcription  errors,  resulting  in saved  time / costs and
          lesser number of chart
     *    Improved clinical decision making with correct data
     *    Automated Vital Signs Integration from Device/Monitoring systems
     *    Increases Profitability for Physicians

EMR  adoption  has  increased  significantly  due to  incentive  funding for EMR
implementation  as part of the  American  Recovery  and  Reinvestment  Act  (See
"Government  Regulations").  Doctors  who  don't  prescribe  electronically  are
penalized  financially.  Although  this  mandate  is  Medicare-driven,  Medicare
collects  statistics  for patients of all ages and  insurance  groups,  not just
those  receiving  Medicare  benefits.  Because of their size and use, we believe
Medicare  requires  will  eventually  drive  conversion  to EMR for all records,
whether Medicare related or not.

Lastly,  we believe EMR adoption  and use is a  significant  beneficiary  of the
Affordable  Care Act.  The Board  census  noted  previously  also  found that 20
million  additional  people  gained  health  coverage over the last 5 five years
through  various  private,   federal  and  state  marketplaces,   which  further
necessitates   the  need  for  simple  to  use  and  productive  EMR  solutions.

COMPETITION AND COMPETITIVE STRATEGY

Although our basic EMR software has been developed, we currently do not have the
financial resources to market and sell it.

Our EMR  software  will be competing in the  healthcare  industry for  primarily
small and medium  sized  physician  offices and  clinics.  The U.S. EMR software
market  currently has many  competitors.  Our competitors  vary in size and cost
structure  from very small  companies  with  limited  resources  to very  large,
diversified  corporations  with greater  financial and marketing  resources than
ours.  We are  considered  the  smallest  as we do  not  currently  our  product
available  for sale or use. We will be  competing  with well  funded  start-ups,
traditional  independent  software  developers  and  manufacturers,   and  fully
integrated  large private and publicly held companies  producing a wide range of
products and services. We will likely face additional competition from the entry
of new companies into our target market.

Our competitors have significantly  greater resources and are able to spend more
time and money on concept and focus testing,  software and product  development,
testing and marketing.  Lead times are  significant for the adoption and regular
use of EMR  software  by any given  small to medium  sized  physician  office or
clinic.   Conversions  of  paper  records  to  EMR  databases   usually  involve
customization and significant time to train personnel and convert paper records.
Competition  is also  based on  product  quality  and  features,  data  storage,
brand-name  recognition,  ease of use,  effectiveness of marketing and price. In
order to compete effectively, we believe we must offer:

                                       4
<PAGE>
     -    Competitive pricing
     -    24 hour user support
     -    99.999% guaranteed uptime for hosted solutions
     -    Rapid development of new features
     -    Incentives and bonuses to clients who refer new customers
     -    Dedicated sales and support staff
     -    Work directly with users to develop features according to their needs
     -    Work  directly  with all the major device  manufacturers  to integrate
          their devices seamlessly into our system

In addition, regardless of our competitor's market position, financial resources
or size, our success also depends on our ability to successfully execute several
other competitive  strategies,  which we believe must  successfully  address the
following for our customers:

INCREASE  OFFICE  PRODUCTIVITY  AND  CLINICAL  WORKFLOW:  Our EMR  product  must
ultimately  reduce office  transition time and resources to convert the existing
paper records, in addition to ongoing daily data record keeping.

CONNECTIVITY AND INTEGRATED AUTOMATION OF PATIENT VITAL SIGNS:  Ultimately,  our
EMR software must have the ability to record patient vital signs directly from a
given monitoring device,  such as a blood pressure monitor,  seamlessly into the
EMR  database.  This  reduces  human data  entry  errors  and  increases  office
productivity.  In the  future,  we plan to  incorporate  this  functionality  by
creating  vital  signs  capture  through  the  use  of an  integrating  software
development   kit  for  use  with  various   diagnostic   monitoring   equipment
manufacturers.

REDUCED  USER COST  THROUGH THE USE OF OPEN SOURCE  SOFTWARE:  We believe we can
achieve a pricing  advantage  over our  competitors,  as our  software  has been
created  from  `open-source  software.'  and  modified  to suit our needs.  As a
result,  our software  development  costs are reduced,  which enables us to pass
these savings onto customers. Open source software is where the original creator
provides  the rights to study,  change and  distribute  the software for free to
anyone and for any  purpose.  Typically,  open  source  software is found on the
internet and is obtained at no cost, free of licensing fees, which enables us to
pass on those savings to our users

DATA BACK-UP:  Our EMR database is backed up instantly when data is entered. The
back up  facilities  can either be managed in house on separate  servers or with
independent third party data storage facilities.

PHYSICIAN/OPERATOR  REMOTE  ACCESS:  Our software  offers  physicians  and their
approved  operators the ability to remotely  login and view patient  records via
secure  access.  We believe  remote access is a competitive  advantage that most
other EMR providers do not provide, and is an invaluable feature when physicians
and care providers not in the office and require patient data.

DATA  SECURITY &  ENCRYPTION:  Data  security is a key aspect of our software to
comply with HIPAA security rules (See "Government  Regulations") and ensure data
security.  Encryption  is the  conversion  of  data  into a form,  often  called
ciphertext,  which  cannot be  understood  by another  party,  human or machine,
without  being  decrypted  first.  Our software  programs and all future  client
installations  have been configured to comply with current HIPPA rules and offer
a high  level of  protection  through  the use of  algorithms  to  scramble  the
original  input data into a new form  which  cannot be read  without  the use of
decryption keys.

                                       5
<PAGE>
In order for our software and our company to be  successful,  we will first need
to alert our target market about our proposed EMR product and the  advantages we
intend to offer our  prospective  customers when we have the financing to do so.
We will also have to develop a comprehensive, ongoing marketing plan to sell the
software.  We believe our marketing  and  promotion  strategy will be subject to
major revisions are we get closer to actually launching the product.

SALES STRATEGY

We are  still  in the  planning  and  formulation  stages  with  respect  to the
commercialization  of our  product.  Our planned  sales  strategy,  as discussed
herein, may change significantly as we get closer to commercialization.

We plan to price our  software  product  competitively.  Current EMR software is
generally  licensed  to the  user by the  developer  or  distributor.  The  user
typically  pays a one time  implementation  fee for the basic  system.  In North
America,  the fee  typically  varies from  $500.00 for single  practitioners  to
$1,500-2,000  for medium sized offices and clinics with 10+  physicians.  Annual
license fees,  which include  technical  support and annual  security/encryption
renewals,  currently  average  approximately  $4,500-7,000  per  year.  Software
development  kits for connectivity to vitals monitors and third party monitoring
equipment is priced in addition to the basic  implementation and licensing fees,
and is generally determined on a case by case basis.

Initially,  we plan to use our  corporate  website and  contract a  professional
sales  consultant  to market  and sell our  proposed  product.  In  addition  to
corporate  information and other standard sections contained on the website,  we
plan to use our website as a sales tool for our  initial  product  release,  new
releases  and  updates,  new industry  trends and  concepts.  We will seek out a
contract professional with extensive experience in Health Information Technology
("HIT") and a solid data base of medical  industry  contacts and  relationships.
HIT  includes  both  basic EMR  recordkeeping  and  databases,  vitals and other
monitor  connectivity.  Additionally,  we  plan  to  focus  all of  our  selling
activities  on the  concept  of return  on  investment  ("ROI")  to both end use
customers and  distributors.  We believe the economic  focus on ROI for adoption
and use of our  product  will  assist  the growth of  initial  sales,  resultant
testimonials and ultimately,  proof that clearly  demonstrates the effectiveness
of our EMR solution.  We believe this will allow us to leverage sales  contracts
early, and ultimately  drive revenue.  This focus should also demonstrate to our
prospective customers that we have a strong grasp on the various components that
contribute to a positive and beneficial ROI to the user.

Ultimately,  we need to demonstrate that the scope of improved efficiency varies
with degree of implementation,  and includes reduced labor costs,  improved cash
flow,   streamlined  clinical  and  financial  management  workflow,   increased
reimbursement,  and detailed financial  reporting,  all of which can potentially
increase profits for our users.

Prior to product launch, we plan to identify various medical conferences, forums
and trade  shows  across the  country,  which  focus on Medical  devices  and/or
information  technology.  Attending a select number of trade shows will be a key
component  of our  initial  sales and  marketing  strategy  to  demonstrate  the
technology and the positive attributes of our solution. These forums include:

     *    Medical Associations (i.e.: American Medical Association)
     *    Trade Shows & Medical conferences
     *    Physician Education Campaigns

                                       6
<PAGE>
DISTRIBUTION OF PRODUCTS OR SERVICES

When our EMR software is ready for  commercial  sale,  we plan to  distribute it
through four primary channels:

Direct Selling:  Our contract sales consultant,  when hired, will be responsible
for  developing  direct sales.  This model will allow the Company to have direct
control and influence over customization for vital sign automation with specific
customers.

Partnerships with diagnostic vital sign monitor  manufacturers:  This channel is
invaluable for two primary reasons.  These manufacturers  already have a captive
audience with physicians and clinics, and they also have significant interest in
developing interoperability with their vital signs equipment.

Medical Distribution  Companies:  This channel would entail medical distribution
supply companies  re-selling our product to our target market. This will involve
establishing  `list  price' and  industry-comparable  distributor  discounts  of
approximately 30-40% off list.

SAAS  model:  Software  as a  service,  meaning  that  our  staff  will  run the
application  and store the  data.  The data  would be  encrypted  and  stored on
secured servers.

Our   distribution   plans  may  change   significantly  as  we  get  closer  to
commercializing our product.

SOURCES AND AVAILABILITY OF PRODUCTS AND SUPPLIES

There are no constraints on the sources or  availability  of outsource  software
developers and supplies related to our business. We have been using either local
third party  software  development  contractors or firms based in Eastern Europe
for development,  and plan to continue doing so for client  installations and to
develop third party interfaces, when we have the necessary financing to do so.

Our  officers  and  directors  will  continue to be  responsible  for the entire
development  and production  process  including  manpower  requirements  and the
supervision and coordination of internal and external resources. We currently do
not anticipate any supply or manpower  availability  constraints with respect to
identifying and choosing any of the contractors we require.

DEPENDENCE ON ONE OR A FEW MAJOR CUSTOMERS

We plan on selling our products and services  directly and  indirectly  to small
and medium sized, end use, physician offices and clinics.  Therefore,  we do not
anticipate dependence on one or a few major customers.

GOVERNMENT REGULATIONS

There are  numerous  laws and  regulations  that  govern  the use,  storage  and
transmission of patient medical records to protect privacy. Laws and regulations
vary  significantly  by country,  and even by state in the USA.  Because patient
privacy is of critical  importance,  laws and regulations are expected to become
even more  burdensome  to protect  against  electronic  theft,  or  unauthorized
transmission or use of patient  records.  In order to comply,  we will likely be

                                       7
<PAGE>
required to modify our software and data storage for each  jurisdiction in which
we intend to sell our product. Additionally, we are unable to predict the impact
that these modifications and future legislation,  legal decisions or regulations
concerning our EMR software may have on our business,  financial condition,  and
results  of  operations.  If we are found to be  negligent  in the design of our
software which results in  unauthorized  transmission or use of patient data, we
could be subject to  lawsuits  and  penalties  which could  severely  affect our
business.

At the federal level in the USA, the privacy of individually identifiable health
information,  the security of electronic protected health information  including
EMRs, and  confidentiality  of  identifiable  information  being used to analyze
patient safety events and improve  patient safety is protected  under the Health
Insurance  Portability and Accountability Act ("HIPPA").  HIPAA requirements and
security  rules give  patients more control over their health  information,  set
limits on the use and release of their medical records, and establishes a series
of privacy  standards for health care  providers  which  provides  penalties for
those who do not follow these standards. EMRs require the use of data encryption
for  transmission  and storage,  ensuring that only the intended  recipients are
able to view  them.  There  are  other  HIPAA  data  security  systems  that are
typically  installed on health care  computer  systems and  networks,  including
firewalls to prevent  unauthorized access, and electronic auditing systems which
require  users to identify  themselves  and which log specific  records that are
accessed by them.  Many health care  providers find it useful to have HIPAA data
security  audits  of  their  systems   performed  on  a  regular  basis.   These
examinations  and  reports,  if addressed  properly,  can serve to ensure a high
level of compliance  and also to mitigate  penalties for  inadvertent  problems.
HIPAA  electronic  medical  records privacy rules allow health care providers to
use  or  disclose  patient  health  information,   such  as  diagnostic  images,
laboratory  tests,  diagnoses,  and  other  medical  information  for  treatment
purposes  without  the  patient's  authorization.   This  includes  sharing  the
information to consult with other providers,  including providers who themselves
are not covered  entities  (as defined by HIPAA),  to aid in the  treatment of a
different patient, or to refer the patient to a specialist.

Our  business is also subject to the HITECH Act (Health  Information  Technology
for  Economic and Clinical  Health)  which is part of the American  Recovery and
Reinvestment  Act of 2009.  The Act, which is considered to be beneficial to our
business,  (provided we can introduce our product in a timely manner),  outlines
many new initiatives for the use of technology in the healthcare  industry,  and
certain  "meaningful  use"  criteria.  Meaningful  use is the  set of  standards
defined by the Centers for Medicare & Medicaid Services (CMS) Incentive Programs
that governs the use of electronic health records and allows eligible  providers
and hospitals to earn incentive payments by meeting specific criteria.  The goal
of  meaningful  use is to promote  the spread of  electronic  health  records to
improve health care in the United States.  The benefits of the meaningful use of
EMR's include:

COMPLETE AND ACCURATE  INFORMATION:  With electronic medical records,  providers
have the information they need to provide the best possible care. Providers will
know more about their  patients and their health  history  before they walk into
the examination room.

BETTER ACCESS TO  INFORMATION:  Electronic  medical records  facilitate  greater
access to the information providers need to diagnose health problems earlier and
improve the health  outcomes of their patients.  Electronic  health records also
allow  information to be shared more easily among doctors'  offices,  hospitals,
and across health systems, leading to better coordination of care.

                                       8
<PAGE>
PATIENT  EMPOWERMENT:  Electronic  health records will help empower  patients to
take a more  active  role in their  health and in the health of their  families.
Patients can receive  electronic copies of their medical records and share their
health information securely over the Internet with their families.

We have developed our basic EMR software and client  installation  procedures to
comply with these regulations, which may be subject to change at our cost at any
time in the future.

PATENT, TRADEMARK,  LICENSE & FRANCHISE RESTRICTIONS AND CONTRACTUAL OBLIGATIONS
& CONCESSIONS

We  currently  do not  own any  intellectual  property  have  not  obtained  any
copyrights,  patents or  trademarks  in respect  of any  intellectual  property.
Software  is  susceptible  to  piracy  and  unauthorized  copying.  Our  primary
protection  against  unauthorized  use,  duplication  and  distribution  of  our
products is copyright and trademark  protection of our software  product and any
related elements and enforcement to protect these interests. As we get closer to
commercializing  and selling our product, we plan to copyright and trademark the
following:

     *    Trademarks  associated  with  elements  of the  software,  such as any
          logos;
     *    Trademarks under which the software is marketed;
     *    the copyrights for the software

We plan to register  copyrights and trademarks in countries  where we distribute
our product.  We may seek other protection over these assets if we have the cash
resources to do so.

We have not entered into any franchise  agreements or other  contracts that have
given, or could give rise to obligations or concessions.

RESEARCH AND DEVELOPMENT ACTIVITIES AND COSTS

Provided we can raise suitable funding, we plan on spending $50,000 for software
development  activities  over 12 months from the date of successful  completion.
This  includes all user input  design,  design and  programming  for our planned
vital signs equipment inoperability kit.

EMPLOYEES AND EMPLOYMENT AGREEMENTS

In addition to being our sole officer and director, Ms. Gallovicova is currently
our only employee.  She is currently planning to devote a minimum of 10-20 hours
per week to company matters,  but has indicated that he will devote more time as
the board of  directors  determines  is  necessary  to manage the affairs of the
company.  There is no formal  employment  agreement  between the Company and Ms.
Gallovicova.

We also plan on hiring a sales consultant  provided we are successful in raising
the additional financing described herein.

ITEM 1A. RISK FACTORS

As a "smaller reporting  company," as defined in Rule 12b-2 of the Exchange Act,
we are not required to provide the information called for by this Item.

                                       9
<PAGE>
ITEM 1B. UNRESOLVED STAFF COMMENTS

None.

ITEM 2. PROPERTIES

We do not currently own any real property.  Our corporate offices are located at
Mlynska 28, 040 01 Kosice,  Slovak Republic. We pay annual rent of $500 for this
shared office space.  This location will serve as our primary  executive offices
for  the  foreseeable   future.   Management   believes  the  current   premises
arrangements are sufficient for its needs for at least the next 12 months.

We currently  have no investment  policies as they pertain to real estate,  real
estate interests or real estate mortgages.

ITEM 3. LEGAL PROCEEDINGS

We are not currently  involved in any legal  proceedings and we are not aware of
any pending or potential legal actions.

ITEM 4. MINE SAFETY DISLOSURES

Not Applicable.

                                    PART II

ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND
        ISSUER PURCHASES OF EQUITY SECURITIES

Our common shares are quoted on the OTC Markets under the ticker symbol ZFLO. As
of the date hereof, there have not been any trades.

HOLDERS

On June 5, 2015 there were 28 holders of record of our common stock.

DIVIDEND POLICY

Historically,  we have not paid any dividends to the holders of our common stock
and we do not expect to pay any such dividends in the foreseeable  future, as we
expect to retain our future  earnings for use in the  operation and expansion of
our business.

RECENT SALES OF UNREGISTERED SECURITIES

None.

                                       10
<PAGE>
SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS

We have not established any compensation plans under which equity securities are
authorized for issuance.

PURCHASES OF EQUITY SECURITIES BY THE REGISTRANT AND AFFILIATED PURCHASERS

We did not purchase any of our shares of common stock or other securities during
the year ended March 31, 2015.

ITEM 6. SELECTED FINANCIAL DATA

As a "smaller reporting  company," as defined in Rule 12b-2 of the Exchange Act,
we are not required to provide the information called for by this Item.

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
        OF OPERATIONS

The following  discussion and analysis of our financial condition and results of
operations  should be read in  conjunction  with our  financial  statements  and
related notes included elsewhere in this report.

GOING CONCERN

Our  auditor's  report  expresses an opinion  over our March 31, 2015  financial
statements  that  substantial  doubt  exists as to whether we can continue as an
ongoing  business.  We have very limited  operations  and no  revenues.  We have
incurred losses from  operations  since  inception.  No revenues are anticipated
until we complete and successfully  commercialize our planned EMR software.  The
ability of our Company to continue as a going  concern is  dependent  on raising
capital  to  fund  our  business  plan  and  ultimately  to  attain   profitable
operations.  Accordingly,  these  factors  raise  substantial  doubt  as to  the
Company's ability to continue as a going concern.

Our   activities  to  date  have  been  financed  from  the  proceeds  of  share
subscriptions and loans from our Director. From our inception to March 31, 2015,
we have  raised a total of $65,000 in gross  proceeds  from the  issuance of our
common stock.  During the year ended March 31, 2015, our Director lent $5,760 to
our  company  to pay for our  existence  and  regulatory  filings.  There  is no
guarantee that we will be able to raise any  additional  funds through any other
offerings or methods.

OVERVIEW

Statements  in this  section  and  elsewhere  in this  Form  10-K  that  are not
statements   of  historical   or  current  fact   constitute   "forward-looking"
statements.

LIMITED OPERATING HISTORY AND NEED FOR ADDITIONAL CAPITAL

Our Company  was  incorporated  in the State of Nevada on  February  25, 2013 to
engage in the  development  and sale of EMR  software  for small to medium sized
physician  offices  and  clinics.  We have very  limited  financial  backing and
assets.  We will  then  need to  raise  additional  financing  to  maintain  our
existence, commercially launch our product and provide additional functionality.

                                       11
<PAGE>
Our long term business objectives are:

     *    Achieve ongoing profitability from the sale of our products and create
          value for our stockholders, users and clients.
     *    Become a  well-recognized  brand for easy to use , cost  effective EMR
          software and connectivity to third party diagnostic equipment
     *    Develop a leadership role over time in our specialty.

We currently have no employees. During the first stages of our company's growth,
our officer  and  director  will  provide her time free of charge to execute our
business plan. Due to limited financial  resources,  she is planning to dedicate
between 10-20 hours per week, to ensure all  operations  are executed.  Since we
intend to operate  with very  limited  administrative  support,  our officer and
director will continue to be responsible for  administering the company at least
until  we  raise  suitable  additional  financing  to  launch  our  product.  If
successful,  we plan on  hiring  one  sales  consultant  for  direct  sales  and
marketing activities.

We cannot  guarantee  we will be  successful  in our  business  operations.  Our
business is subject to all of the risks inherent in the  establishment  of a new
business  enterprise  and we are a number of months  away  from  generating  any
revenue, if at all.

12 MONTH PLAN OF OPERATION

Our plan of operations  over the next 12 month period is focused  exclusively on
raising additional  capital. We currently estimate we will require an additional
$200,000  for  corporate  existence,  the  commercial  launch  of our  basic EMR
software and another 8-10 months  (subsequent to the completion of our basic EMR
software)   and   $50,000  to  develop   the   software   development   kit  for
interoperability  with third parties.  We do not have any  arrangements in place
for this additional financing.

Our  commercial  launch  budget  also  includes  approximately  $20,000  for the
development of an automated  software  deployment system which will enable us to
either run the software for licensed users on our servers,  or sell our software
to clients  via the  internet.  Fixes and  updates  can also be easily  deployed
through this system,  ensuring that all of our clients are running on the latest
version.  We also plan to hire a contract sales  consultant at a monthly cost of
$3,000.  His or her  initial  responsibilities  will focus on the  selection  of
several beta test clients to test our software prior to commercial sale.

Ms.  Gallovicova  will also be  responsible  for all financing  activities,  and
developing  all  job  specifications  for  our  third  party  contract  software
developers  or  firms.  She  will  also be  responsible  for  hiring  the  sales
consultant,  and will oversee the sales consultant in their role specifically as
beta test subjects are selected and the marketing plan is developed.

Without additional financing on a timely basis, our business will fail.

RESULTS OF OPERATIONS

We  incurred a loss of $22,438  for the year ended  March 31,  2015  compared to
$50,947 for March 31, 2014. Our 2015 loss includes $17,050 for professional fees

                                       12
<PAGE>
and $5,388 for general and administrative  costs. Our 2014 loss includes $40,643
for professional fees and $10,304 for general and administrative costs.

We have incurred  cumulative  losses of $73,940.  We believe we will continue to
incur losses into the foreseeable future as we develop our business.

REVENUES

We did not generate any revenues in 2014 or 2015.  Future revenue  generation is
dependent on the successful  commercial launch of our EMR product,  for which we
need significant financing to market and sell our product.

LIQUIDITY AND CAPITAL RESOURCES

Historically, we have financed our cash flow and operations solely from the sale
of common stock and loans from our Director.

We started  our fiscal year  ending  March 31, 2015 with  $13,498 in net working
capital. As previously indicated, we received $5,760 in loan proceeds during the
year from our Director. The loan is non interest bearing, has no repayment terms
and is due on demand.  During the year ended March 31, 2015,  we used $19,358 in
cash for our operations. As a result, our remaining cash balance as of March 31,
2014 was $NIL and we had a working  capital  deficiency of $8,940  including the
loan.

Our continued corporate existence is solely dependent on further loans or equity
financing.  We  currently  have  no  cash  to  continue.  We  still  must  raise
significant additional funding to continue with our business. If we cannot raise
additional  financing,  we will be forced to cease  operations  and our business
will fail.

These funds will have to be raised through equity financing,  debt financing, or
other sources,  which may result in the dilution in the equity  ownership of our
shares.  We will  also need more  funds if the  costs of  commercialization  and
further  development  are greater  than we have  budgeted.  We will also require
additional financing to sustain our business operations if we are ultimately not
successful in earning  revenues.  We currently do not have any  arrangements for
further  financing  and we may not be able to obtain  financing  when  required.
Obtaining  commercial  loans,  assuming  those  loans would be  available,  will
increase our liabilities and future cash commitments.

There are no assurances  that we will be able to obtain  further funds  required
for our continued operations.  Even if additional financing is available, it may
not be  available  on  terms  we find  favorable.  At this  time,  there  are no
anticipated  sources of additional funds in place.  Failure to secure the needed
additional  financing  will have an adverse  effect on our  ability to remain in
business.

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

We do not expect the adoption of any recently issued  accounting  pronouncements
to  have a  significant  impact  on our net  results  of  operations,  financial
position, or cash flows.

                                       13
<PAGE>
OFF-BALANCE SHEET ARRANGEMENTS

We have no off-balance sheet arrangements.

SUBSEQUENT EVENTS

None.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a "smaller reporting  company," as defined in Rule 12b-2 of the Exchange Act,
we are not required to provide the information called for by this Item.

                                       14
<PAGE>
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.

                                   Zlato Inc.

                             March 31, 2015 and 2014

Report of Independent Registered Public Accounting Firm                       16

Balance Sheets as of March 31, 2015 and 2014                                  17

Statements of Operations for the Years Ended March 31, 2015 and 2014          18

Statement of Stockholders' Equity for the Years Ended March 31, 2015
and 2014                                                                      19

Statements of Cash Flows for the Years Ended March 31, 2015 and 2014          20

Notes to the Financial Statements                                             21

                                       15
<PAGE>
                          PLS CPA, A Professional Corp.
        * 4725 MERCURY STREET SUITE 210 * SAN DIEGO * CALIFORNIA 92111 *
      * TELEPHONE (858) 722-5953 * FAX (858) 761-0341 * FAX (858) 764-5480
                         * E-MAIL changgpark@gmail.com *


             REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and
Stockholders of Zlato, Inc.

We have audited the accompanying balance sheet of Zlato, Inc. (the "Company") as
of  March  31,  2015  and  2014,  and  the  related  statements  of  operations,
stockholders'  equity,  and cash flows for the years then ended.  The  Company's
management is responsible for these financial statements.  Our responsibility is
to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance  with the standards of the Public  Company
Accounting Oversight Board (United States). Those standards require that we plan
and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement.  An audit includes examining, on a
test basis,  evidence  supporting  the amounts and  disclosures in the financial
statements.  An audit also includes assessing the accounting principles used and
significant  estimates  made by  management,  as well as evaluating  the overall
financial  statement  presentation.   We  believe  that  our  audits  provide  a
reasonable basis for our opinion.

In our opinion,  the financial  statements  referred to above present fairly, in
all material  respects,  the financial  position of Zlato,  Inc. as of March 31,
2015 and 2014,  and the  results  of its  operations  and its cash flows for the
years then ended in conformity with accounting  principles generally accepted in
the United States of America.

The  financial  statements  have been  prepared  assuming  that the Company will
continue as a going concern. As discussed in Note 3 to the financial statements,
the Company's losses from operations raise  substantial  doubt about its ability
to continue as a going  concern.  The  financial  statements  do not include any
adjustments that might result from the outcome of this uncertainty.


/s/ PLS CPA
-----------------------------
PLS CPA, A Professional Corp.
June 12, 2015
San Diego, CA. 92111



          Registered with the Public Company Accounting Oversight Board


                                       16
<PAGE>
                                   ZLATO INC.

                                 BALANCE SHEETS

<TABLE>
<CAPTION>
                                                             March 31, 2015        March 31, 2014
                                                             --------------        --------------
<S>                                                          <C>                   <C>
ASSETS

Current assets
  Cash and bank accounts                                        $     --              $ 13,598
                                                                --------              --------
      Total current assets                                            --                13,598
                                                                --------              --------

Total assets                                                    $     --              $ 13,598
                                                                ========              ========

LIABILITIES AND STOCKHOLDERS' DEFICIT

Current liabilities
  Accounts payable                                              $  3,180              $    100
  Due to Director                                                  5,760                    --
                                                                --------              --------
      Total current liabilities                                    8,940                   100
                                                                --------              --------
Stockholders' deficit
  Authorized:
    75,000,000 common shares
    Par value $0.001
  Issued and outstanding:
    6,000,000 common shares                                        6,000                 6,000
  Additional paid-in capital                                      59,000                59,000
  Accumulated deficit                                            (73,940)              (51,502)
                                                                --------              --------
      Total stockholders' (deficit) equity                        (8,940)               13,498
                                                                --------              --------

Total liabilities and stockholders' deficit                     $     --              $ 13,598
                                                                ========              ========
</TABLE>


   The accompanying notes are an integral part of these financial statements.

                                       17
<PAGE>
                                   ZLATO INC.

                            STATEMENTS OF OPERATIONS

<TABLE>
<CAPTION>
                                                 Year Ended           Year Ended
                                               March 31, 2015       March 31, 2014
                                               --------------       --------------
<S>                                            <C>                  <C>
REVENUE                                          $       --           $       --

OPERATING EXPENSES
  General & administrative                            5,388               10,304
  Professional fees                                  17,050               40,643
                                                 ----------           ----------
Loss before income taxes                            (22,438)             (50,947)

Provision for income taxes                               --                   --
                                                 ----------           ----------

Net loss                                         $  (22,438)          $  (50,947)
                                                 ==========           ==========
Basic and diluted loss per
 Common share (1)
                                                 ==========           ==========
Weighted average number of
 common shares outstanding                        6,000,000            5,453,808
                                                 ==========           ==========
</TABLE>

----------
(1) less than $0.01


   The accompanying notes are an integral part of these financial statements.

                                       18
<PAGE>
                                   ZLATO INC.

                       STATEMENTS OF STOCKHOLDERS' DEFICIT

<TABLE>
<CAPTION>
                                          Common Stock          Additional                        Total
                                       -------------------       Paid in       Accumulated     Stockholders'
                                       Shares       Amount       Capital          Stage           Equity
                                       ------       ------       -------          -----           ------
<S>                                  <C>          <C>           <C>               <C>            <C>
Balance March 31, 2013               5,000,000     $ 5,000      $ 10,000        $    (555)      $ 14,445

Common stock issued for cash         1,000,000       1,000        49,000               --         50,000

Net loss for the period                     --          --            --          (50,947)       (50,947)
                                     ---------     -------      --------        ---------       --------
Balance March 31, 2014               6,000,000       6,000        59,000          (51,502)        13,498

Net loss for the period                     --          --            --          (22,438)       (22,438)
                                     ---------     -------      --------        ---------       --------

Balance March 31, 2015               6,000,000     $ 6,000      $ 59,000        $ (73,940)      $ (8,940)
                                     =========     =======      ========        =========       ========
</TABLE>


   The accompanying notes are an integral part of these financial statements.

                                       19
<PAGE>
                                   ZLATO INC.

                            STATEMENTS OF CASH FLOWS

<TABLE>
<CAPTION>
                                                            Year Ended            Year Ended
                                                          March 31, 2015        March 31, 2014
                                                          --------------        --------------
<S>                                                       <C>                   <C>
OPERATING ACTIVITIES
  Net loss for the period                                    $(22,438)             $(50,947)
  Changes in operating assets and liabilities:
    Accounts payable                                            3,080                   100
                                                             --------              --------
Net cash used for operating activities                        (19,358)              (50,847)
                                                             --------              --------
FINANCING ACTIVITIES
  Loan from director                                            5,760                    --
  Proceeds from issuance of common stock                           --                50,000
                                                             --------              --------
Net cash provided by financing activities                       5,760                50,000
                                                             --------              --------

Decrease in cash during the period                            (13,598)                 (847)

Cash, beginning of the period                                  13,598                14,445
                                                             --------              --------

Cash, end of the period                                      $     --              $ 13,598
                                                             ========              ========

Supplemental disclosure with respect to cash flows:
  Cash paid for income taxes                                 $     --              $     --
  Cash paid for interest                                     $     --              $     --
</TABLE>


   The accompanying notes are an integral part of these financial statements.

                                       20
<PAGE>
                                   ZLATO INC.

                          NOTES TO FINANCIAL STATEMENTS
                                 March 31, 2015


NOTE 1. GENERAL ORGANIZATION AND BUSINESS

The Company was originally incorporated under the laws of the state of Nevada on
February  25,  2013.  The Company is devoting  substantially  all of its present
efforts to establish a new business,  and has had no revenues from operations to
date.

Initial operations have included organization and capital formation.  Management
also has recently  developed  electronic  medical  record  software for small to
medium  sized  physician  offices  and  clinics,  and is  planning  to market it
commercially when they can successfully raise the financing to do so.

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Accounting Basis
The accounting and reporting  policies of the Company conform to U.S.  generally
accepted accounting  principles.  In the opinion of management,  all adjustments
considered  necessary for fair  presentation have been included in the financial
statements.

Basis of Presentation
The financial  statements  of the Company have been  prepared  using the accrual
basis of accounting in accordance with generally accepted accounting  principles
in the United States of America and are presented in U.S.  dollars.  The Company
has adopted a March 31 fiscal year end.

Dividends
The Company has not yet adopted any policy  regarding  payment of dividends.  No
dividends have been paid during the periods shown.

Cash
The  Company's  cash  consists of funds  deposited  with its lawyer into the law
firm's trust account.

                                       21
<PAGE>
                                   ZLATO INC.

                          NOTES TO FINANCIAL STATEMENTS
                                 March 31, 2015


NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Earnings per Share
The basic earnings  (loss) per share is calculated by dividing the Company's net
income available to common shareholders by the weighted average number of common
shares during the year. The diluted  earnings  (loss) per share is calculated by
dividing the Company's net income (loss) available to common shareholders by the
diluted  weighted  average  number of shares  outstanding  during the year.  The
diluted  weighted  average  number of shares  outstanding  is the basic weighted
number  of  shares  adjusted  as of the  first of the  year for any  potentially
dilutive  debt or equity.  The Company has not issued any options or warrants or
similar securities since inception.

Foreign Currency Translation
The Company has adopted the US dollar as its functional  and reporting  currency
because most of its transactions are denominated in US currency.

Fair Value of Financial Instruments
The  Company  estimates  the  fair  value of  financial  instruments  using  the
available market  information and valuation  methods.  Considerable  judgment is
required in estimating fair value. Accordingly,  the estimates of fair value may
not be indicative  of the amounts the Company could realize in a current  market
exchange.

Income Taxes
A deferred  tax asset or liability  is recorded  for all  temporary  differences
between  financial  and tax  reporting  and net  operating  loss  carryforwards.
Deferred tax expense  (benefit)  results from the net change  during the year of
deferred tax assets and liabilities.

Deferred tax assets are reduced by a valuation allowance when, in the opinion of
management, it is more likely than not that some portion, or all of the deferred
tax  assets,  will not be  realized.  Deferred  tax assets and  liabilities  are
adjusted  for the  effects  of  changes  in tax  laws  and  rates on the date of
enactment.

                                       22
<PAGE>
                                   ZLATO INC.

                          NOTES TO FINANCIAL STATEMENTS
                                 March 31, 2015


NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Revenue Recognition
The Company will recognize revenue when products are fully delivered or services
have been provided and collection is reasonably assured.

Use of Estimates
The preparation of financial statements in conformity with accounting principles
generally  accepted in the United States of America requires  management to make
estimates  and  assumptions  that  affect  the  reported  amounts  of assets and
liabilities  and disclosure of contingent  assets and liabilities at the date of
the financial statements and the reported amounts of revenue and expenses during
the reporting period. Actual results could differ from those estimates.

Recent Accounting Pronouncements
The  Company  does  not  expect  the  adoption  of  recently  issued  accounting
pronouncements  to  have a  significant  impact  on  the  Company's  results  of
operations, financial position or cash flow.

NOTE 3. GOING CONCERN

The  accompanying  financial  statements  have been  prepared  assuming that the
Company  will  continue  as a going  concern,  which  contemplates,  among other
things,  the realization of assets and satisfaction of liabilities in the normal
course of business. The Company has net losses from the date of incorporation on
February  25, 2013 to March 31,  2015 of $73,940.  The ability of the Company to
continue as a going concern is dependent upon the Company's  successful  efforts
to either generate  revenues or raise sufficient  capital for its business plans
and then attain profitable operations.  In response to these issues,  management
has planned the following actions:

     -    The Company intends to fund its  expenditures  through loans or equity
          financing arrangements, which may be insufficient to fund its proposed
          development expenditures,  working capital and other cash requirements
          through the next fiscal year.

     -    Management  is  currently   formulating  plans  to  develop  and  sell
          electronic medical records software to generate future revenues. There
          can be no  assurances,  however,  that  management's  expectations  of
          future revenues will be realized.

                                       23
<PAGE>
                                   ZLATO INC.

                          NOTES TO FINANCIAL STATEMENTS
                                 March 31, 2015


NOTE 3. GOING CONCERN (continued)

Management  estimates  the minimum  amount of  additional  funding  necessary to
enable the Company to carry out its intended business plan and remain viable for
at least the twelve months  following  the date of the  financial  statements is
approximately  $50,000.  These factors,  among others,  raise  substantial doubt
about the  Company's  ability to continue as a going  concern.  These  financial
statements do not include any adjustments  that might result from the outcome of
this uncertainty.

NOTE 4. STOCKHOLDERS' EQUITY

Authorized

The Company is authorized to issue 75,000,000  shares of $0.001 par value common
stock. All common stock shares have equal voting rights,  are non-assessable and
have one vote per share.  Voting rights are not cumulative and,  therefore,  the
holders of more than 50% of the common  stock  could,  if they  choose to do so,
elect all of the directors of the Company.

Issued and Outstanding

On February 25, 2013  (inception),  the Company issued  5,000,000  shares of its
common  shares to its  President,  Secretary  Treasurer and Director for cash of
$.003 per share or$15,000 in aggregate.  See Note 5. On September 30 and October
31, 2013 the Company accepted  subscriptions  under its registered  offering for
1,000,000  shares  of common  stock  for cash of $0.05  per  share or  aggregate
proceeds of $50,000.

NOTE 5. RELATED PARTY TRANSACTIONS

The Company's officer and director is involved in other business  activities and
may,  in the  future,  become  involved in other  business  opportunities.  If a
specific  business  opportunity  becomes  available,  such  persons  may  face a
conflict in selecting  between the Company and their other  business  interests.
The Company has not formulated a policy for the resolution of such conflicts.

On February 25, 2013, the Company issued 5,000,000 shares of its common stock to
its President, Secretary Treasurer and Director for cash of $15,000. See Note 4.

During the year ended March 31,  2015,  the  Director  of the  Company  advanced
$5,760 to the Company to pay  expenses on behalf of the  Company.  The  advances
bear no interest, are unsecured, and due on demand.

                                       24
<PAGE>
                                   ZLATO INC.

                          NOTES TO FINANCIAL STATEMENTS
                                 March 31, 2015


NOTE 6. INCOME TAXES

Net deferred tax assets are $0.  Realization of deferred tax assets is dependent
upon  sufficient  future  taxable  income  during  the  period  that  deductible
temporary  differences and carry-forwards are expected to be available to reduce
taxable  income.  As the  achievement  of  required  future  taxable  income  is
uncertain, the Company recorded a 100% valuation allowance.  Management believes
it is likely that any deferred tax assets will not be realized.

                                           March 31, 2015        March 31, 2014
                                           --------------        --------------

Net loss before taxes                         $ 22,438              $ 50,947
Statutory rate                                      35%                   35%
                                              --------              --------

Computed expected tax recovery                   7,853                17,832
Change in valuation allowance                   (7,853)              (17,832)
                                              --------              --------

Income tax provision                          $     --              $     --
                                              ========              ========

The  accumulated  net loss before  taxes is $73,940,  resulting  in an aggregate
deferred  tax  asset/recovery  of  $25,879.  The  Company  has  recorded  a 100%
valuation allowance due to the uncertainty of realization.

The Company's aggregate net operating losses of $73,940 expire as follows:

March 31, 2033 -        $    555
March 31, 2034 -          50,947
March 31, 2035 -          22,438
                        --------
                        $ 73,940
                        ========

NOTE 7. SUBSEQUENT EVENTS

We have  evaluated  subsequent  events  through to the date of  issuance  of the
financial  statements,  and did not have any  material  recognizable  subsequent
events after March 31, 2015.

                                       25
<PAGE>
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
        FINANCIAL DISCLOSURE

None.

ITEM 9A. CONTROLS AND PROCEDURES

DISCLOSURE CONTROLS AND PROCEDURES

Under the supervision and with the  participation  of our management,  including
our principal  executive  officer and the principal  financial  officer,  we are
responsible for conducting an evaluation of the  effectiveness of the design and
operation of our internal controls and procedures, as defined in Rules 13a-15(e)
and 15d-15(e)  under the  Securities  Exchange Act of 1934, as of the end of the
fiscal year covered by this report.  Disclosure  controls and  procedures  means
that the  material  information  required to be included in our  Securities  and
Exchange  Commission  ("SEC")  reports is recorded,  processed,  summarized  and
reported  within the time periods  specified in SEC rules and forms  relating to
our company, including any consolidating subsidiaries,  and was made known to us
by others within those entities, particularly during the period when this report
was being prepared.  Based on this evaluation,  our principal  executive officer
and principal  financial  officer  concluded as of the evaluation  date that our
disclosure controls and procedures were not effective as of March 31, 2015.

MANAGEMENT'S ANNUAL REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING

As of March 31,  2015,  management  assessed the  effectiveness  of our internal
control over financial  reporting.  The Company's  management is responsible for
establishing and maintaining  adequate internal control over financial reporting
for the Company.  Internal  control over financial  reporting is defined in Rule
13a-15(f) or 15d-15(f) promulgated under the Securities Exchange Act of 1934, as
amended,  as a process  designed by, or under the  supervision of, the Company's
President and Chief  Executive  Officer and effected by the  Company's  Board of
Directors,  management  and other  personnel,  to provide  reasonable  assurance
regarding  the  reliability  of  financial  reporting  and  the  preparation  of
financial statements for external purposes in accordance with GAAP in the United
States of America and includes those policies and procedures that:

     *    Pertain  to the  maintenance  of  records  that in  reasonable  detail
          accurately and fairly reflect our transactions and dispositions of our
          assets;
     *    Provide   reasonable   assurance  our  transactions  are  recorded  as
          necessary  to  permit  preparation  of  our  financial  statements  in
          accordance  with GAAP,  and that receipts and  expenditures  are being
          made only in accordance  with  authorizations  of our  management  and
          directors; and
     *    Provide reasonable  assurance regarding prevention or timely detection
          of  unauthorized  acquisition,  use or  disposition of our assets that
          could have a material effect on the financial statement.

In  evaluating  the   effectiveness  of  our  internal  control  over  financial
reporting,  our  management  used the  criteria  set forth by the  Committee  of
Sponsoring Organizations of the Treadway Commission ("COSO") in Internal Control
- Integrated Framework. Based on that evaluation, completed by Dana Gallovicova,
our  President  and Chief  Executive  Officer,  who also serves as our principal
accounting and principal  financial  officer,  Ms.  Gallovicova  concluded that,

                                       26
<PAGE>
during the period covered by this report,  such internal controls and procedures
were not effective to detect the  inappropriate  application of US GAAP rules as
more fully described below.

This was due to  deficiencies  that  existed in the design or  operation  of our
internal controls over financial  reporting that adversely affected our internal
controls  and that may be  considered  to be  material  weaknesses.  The matters
involving internal controls and procedures that our management  considered to be
material  weaknesses  under  the  standards  of the  Public  Company  Accounting
Oversight Board were: (i) lack of a functioning audit committee due to a lack of
a majority of independent  members and a lack of a majority of outside directors
on  our  board  of  directors,   resulting  in  ineffective   oversight  in  the
establishment and monitoring of required internal controls and procedures;  (ii)
inadequate  segregation of duties consistent with control objectives;  and (iii)
ineffective   controls  over  period  end  financial  disclosure  and  reporting
processes.  The  aforementioned  material  weaknesses  were  identified  by  our
President and Chief Executive Officer who also serves as our principal financial
and  accounting  officer,  in  connection  with  the  review  of  our  financial
statements as of March 31, 2015.

Management  believes that the lack of a functioning audit committee and the lack
of a  majority  of  outside  directors  on our  board of  directors  results  in
ineffective  oversight in the  establishment and monitoring of required internal
controls and  procedures,  which could result in a material  misstatement in our
financial statements in future periods.

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

There were no changes in the Company's internal control over financial reporting
that  occurred  during the fourth  quarter of the year ended March 31, 2015 that
have materially  affected,  or that are reasonably likely to materially  affect,
the Company's internal control over financial reporting.

ITEM 9B. OTHER INFORMATION

None.

                                    PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

All  directors of our company  hold office until the next annual  meeting of the
stockholders  or until their  successors  have been elected and  qualified.  The
officers of our company are  appointed by our board of directors and hold office
until their  death,  resignation  or removal  from  office.  Our  directors  and
executive  officers,  their ages,  positions  held, and duration as such, are as
follows:

                                                              Date First Elected
     Name          Position Held with the Company     Age        or Appointed
     ----          ------------------------------     ---        ------------

Dana Gallovicova     President, CEO Secretary,         42     February 25, 2013
                     Treasurer and Director

                                       27
<PAGE>
BUSINESS EXPERIENCE

The following is a brief  account of the  education  and business  experience of
each  director  and  executive  officer  during at least  the past  five  years,
indicating each person's business  experience,  principal  occupation during the
period,  and the name and principal business of the organization by which he was
employed.

MS. DANA GALLOVICOVA, SECRETARY TREASURER AND MEMBER OF THE BOARD OF DIRECTORS

Ms. Gallovicova has been serving as our President,  CEO, Secretary Treasurer and
a Director  since  February 25, 2013. The term of her office is for one year and
is renewable on an annual basis.

She received an Economics Diploma from the Business Academy of Kosice,  Slovakia
in 1991 and a Nursing Care  Certificate  from the Nursing College of Bratislava,
Slovakia in 1995. She has acted as the Executive Assistant to the Mayor's Office
for the City of Kosice,  Slovakia since 2005.  Kosice is the second largest city
in Slovakia Republic with a population of approximately 250,000 inhabitants. Her
duties  include  oversight  of  over  5,000  property  tax  accounts  and she is
responsible for assessments,  invoicing and collections. She is also responsible
for  planning  and  organizing  civic  functions  and events for the Mayor,  and
assists the City Manager with civic budgets,  related presentations and business
plans for the city. These experiences, qualifications and attributes have led to
our conclusion that Ms.  Gallovicova  should be serving as a member of our Board
of Directors in light of our business and structure.

She is currently  devoting  approximately  10-20 hours a week of his time to our
company,  and is  planning to devote 40 hours per week if  necessary  during the
next 12 months of operation.

She is not an officer or director of any  reporting  company that files  annual,
quarterly,  or periodic  reports with the United States  Securities and Exchange
Commission.

BOARD COMPOSITION

Our Bylaws provide that the Board of Directors  shall consist of no less than 1,
but not more than 8  directors.  Each  director  serves  until his  successor is
elected and qualified.

COMMITTEES OF THE BOARD OF DIRECTORS

We do not presently have a separately constituted audit committee,  compensation
committee,  nominating committee, executive committee or any other committees of
our Board of Directors. Nor do we have an audit committee "financial expert." As
such,  our entire Board of  Directors  acts as our audit  committee  and handles
matters related to compensation and nominations of directors.

SIGNIFICANT EMPLOYEES

We have no  significant  employees  other than the sole  executive  officer  and
director described above.

                                       28
<PAGE>
FAMILY RELATIONSHIPS

There are no familial relationships between our officers and directors.

CERTAIN LEGAL PROCEEDINGS

No  director,  nominee for  director,  or  executive  officer of the Company has
appeared as a party in any legal  proceeding  material to an  evaluation  of his
ability or integrity during the past five years.

SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE

Section  16(a) of the  Securities  Exchange Act of 1934  requires our  executive
officers  and  directors,  and  persons  who own  more  than  ten  percent  of a
registered class of our equity securities, file reports of ownership and changes
in ownership with the SEC. Executive  officers,  directors and  greater-than-ten
percent  stockholders  are  required by SEC  regulations  to furnish us with all
Section  16(a) forms they file.  Based on our review of filings  made on the SEC
website,   and  the  fact  of  us  not   receiving   certain  forms  or  written
representations  from certain reporting persons that they have complied with the
relevant filing  requirements,  we believe that, during the year ended March 31,
2014,  all of our executive  officers,  directors and  greater-than-ten  percent
stockholders complied with all Section 16(a) filing requirements.

CODE OF ETHICS

The  Company  has not  adopted a code of ethics  that  applies to its  principal
executive officers, principal financial officer, principal accounting officer or
controller, or persons performing similar functions. The Company has not adopted
a code of ethics because it has only commenced operations.

ITEM 11. EXECUTIVE COMPENSATION

The following table sets forth  information with respect to compensation paid by
us to our sole officer for the fiscal periods indicated:

SUMMARY COMPENSATION TABLE

<TABLE>
<CAPTION>
                                                                                        Change in
                                                                                         Pension
                                                                                         Value &
                                                                          Non-Equity   Nonqualified
                                                                          Incentive     Deferred       All
  Name and                                                                   Plan        Compen-      Other
 Principal                                            Stock      Option    Compen-       sation       Compen-
  Position             Year   Salary($)  Bonus($)   Awards($)   Awards($)  sation($)    Earnings($)  sation($)  Totals($)
------------           ----   ---------  --------   ---------   ---------  ---------    -----------  ---------  ---------
<S>                    <C>       <C>       <C>          <C>        <C>        <C>           <C>         <C>        <C>
Dana Gallovicova       2015       0         0           0           0          0             0           0          0
President, CEO         2014       0         0           0           0          0             0           0          0
Secretary, Treasurer
</TABLE>

                                       29
<PAGE>
Subsequent to the date our date of incorporation,  our executive officer has not
received and are not accruing any compensation. She anticipates this arrangement
will  remain in effect  for the next 12  months.  We have not  entered  into any
employment  or  consulting  agreements  with our  sole  director  and  executive
officer.

OUTSTANDING EQUITY AWARDS AT 2015 FISCAL YEAR-END

We do not currently  have a stock option plan or any long-term  incentive  plans
that provide compensation as an incentive for performance.  We have not made any
individual stock option grants or other equity incentive awards to our executive
officer and director since our inception.

EMPLOYMENT CONTRACTS

The Company has not entered into an  employment  agreement  with its officer and
director during the year ended March 31, 2015.

DIRECTOR COMPENSATION TABLE

<TABLE>
<CAPTION>
                                                                             Change in
                                                                              Pension
                            Fees                                             Value and
                           Earned                           Non-Equity      Nonqualified     All
                             or                              Incentive        Deferred      Other
                           Paid in    Stock      Option        Plan         Compensation   Compen-
    Name                   Cash($)   Awards($)  Awards($)  Compensation($)   Earnings($)   sation($)  Total($)
    ----                   -------   ---------  ---------  ---------------   -----------   ---------  --------
<S>                           <C>       <C>        <C>           <C>             <C>          <C>        <C>
Dana Gallovicova    2015      0          0          0             0               0            0         0
                    2014      0          0          0             0               0            0         0
</TABLE>

We have no formal plan for  compensating  our  director  for her services in her
capacity as director.  Our director is entitled to reimbursement  for reasonable
travel and other  out-of-pocket  expenses incurred in connection with attendance
at meetings of our board of directors.  The board of directors may award special
remuneration to any director undertaking any special services on behalf of Zlato
other than services  ordinarily  required of a director.  Since inception to the
date  hereof,  no director  received  and/or  accrued any  compensation  for his
services  as  a  director,  including  committee  participation  and/or  special
assignments.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND
         RELATED STOCKHOLDERS MATTERS

PRINCIPAL SHAREHOLDERS

The following  table lists, as of March 31, 2015, the number of shares of common
stock of our Company  that are  beneficially  owned by (i) each person or entity
known  to  our  Company  to be the  beneficial  owner  of  more  than  5% of the
outstanding  common  stock;  (ii) each officer and director of our Company;  and
(iii) all officers and directors as a group.  Information relating to beneficial
ownership of common stock by our principal  shareholders and management is based
upon information furnished by each person using "beneficial  ownership" concepts

                                       30
<PAGE>
under the rules of the Securities and Exchange Commission.  Under these rules, a
person is deemed to be a  beneficial  owner of a security  if that person has or
shares  voting power,  which  includes the power to vote or direct the voting of
the security,  or investment  power,  which includes the power to vote or direct
the voting of the security.  The person is also deemed to be a beneficial  owner
of any security of which that person has a right to acquire beneficial ownership
within 60 days. Under the Securities and Exchange  Commission  rules,  more than
one person may be deemed to be a beneficial owner of the same securities,  and a
person may be deemed to be a beneficial  owner of  securities  as to which he or
she may not have any pecuniary beneficial interest.  Except as noted below, each
person has sole voting and investment power.

<TABLE>
<CAPTION>
                                                               Amount and
                                           Amount and           Nature of
                                            Nature of          Beneficial        Percent
                                            Beneficial          Ownership        of Class
Title of      Name and Address of         Ownership Prior      Subsequent        Prior to
 Class         Beneficial Owner            to Offering         to Offering      Offering(2)
 -----         ----------------            -----------         -----------      -----------
<S>                                         <C>                 <C>                <C>
Common      Dana Gallovicova                5,000,000           5,000,000          83.33%
            Mlynska 28, 040 01
            Kosice, Slovak Republic

Common      Directors and officers
            as a group (1)                  5,000,000           5,000,000          83.33%
</TABLE>

----------
1.   Represents beneficial ownership
2.   Based on the total of 6,000,000  outstanding  common  shares as of the date
     hereof

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR
         INDEPENDENCE

Ms.  Gallovicova  purchased  5,000,000 shares of our common stock for $0.003 per
share. All of these shares are restricted  securities,  and are held by the sole
officer and director of our Company. (See "Principal Shareholders".)

During the fiscal year ended March 31, 2015,  Ms.  Gallovicova  lent our company
$5,760  to pay  for  certain  of our  regulatory  filings  and to  maintain  our
corporate  existence.  The  loan  is non  interest  bearing,  has  no  specified
repayment terms and is due on demand.

POTENTIAL CONFLICTS OF INTEREST

Since we do not have an audit or compensation committee comprised of independent
directors,  the functions that would have been performed by such  committees are
performed by our directors.  Thus, there is a potential  conflict of interest in
that  our  directors  and  officers  have  the  authority  to  determine  issues
concerning  management  compensation and audit issues that may affect management
decisions.  Our officers and directors  have  conflicts of interest in that they
have other time  commitments  that will prevent them from devoting  full-time to
our operations,  which may affect our operations.  We are not aware of any other
conflicts of interest with any of our executives or directors.

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

The aggregate  fees billed during the fiscal years ended March 31, 2015 and 2014
for professional  services rendered by PLS CPA, A Professional Corp. and Goldman
Accounting  Services CPA, PLLC,  with respect to the audits of our 2015 and 2014
financial  statements,  as  well  as  their  quarterly  reviews  of our  interim

                                       31
<PAGE>
financial   statements  and  services   normally  provided  by  the  independent
accountant in connection  with statutory and  regulatory  filings or engagements
for these fiscal periods, were as follows:

                                              Year Ended           Year Ended
                                            March 31, 2015       March 31, 2014
                                            --------------       --------------

Audit Fees and Audit Related Fees              $  8,000             $  4,750
Tax
Fees                                                 --                   --
All Other
Fees                                                300                1,000
                                               --------             --------
TOTAL                                          $  8,300             $  5,750
                                               ========             ========

PRE APPROVAL POLICIES AND PROCEDURES

We do not have a separately  designated Audit Committee.  The Board of Directors
pre-approves all services provided by our independent auditors. All of the above
services and fees were  reviewed  and approved by the Board of Directors  either
before or after the respective services were rendered.

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES.

Exhibit
Number                           Description
------                           -----------

3.1      Articles of Incorporation (1)

3.2      Bylaws (1)

31.1     Certification of Principal Executive Officer pursuant to Section 302 of
         the Sarbanes-Oxley Act of 2002.

31.2     Certification of Principal Financial Officer pursuant to Section 302 of
         the Sarbanes-Oxley Act of 2002.

32.1     Certification of Principal  Executive and Principal  Financial  Officer
         and pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101      Interactive data files pursuant to Rule 405 of Regulation S-T. (2)

----------
(1)  Incorporated  by reference to the  Registrant's  Registration  Statement on
     Form S-1 (File No. 333-188610), filed with the Commission on May 15, 2013.
(2)  Incorporated  by reference to the  Registrant's  Annual Report on Form 10-K
     (File No. 000-55023), filed with the Commission on June 12, 2015.

                                       32
<PAGE>
                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.

                                        ZLATO INC.


Date: January 4, 2016                   By: /s/ Dana Gallovicova
                                            ------------------------------------
                                            President, CEO, Secretary
                                            Treasurer, Principal Executive,
                                            Financial and Accounting Officer


                                       33
<PAGE>
                                  EXHIBIT INDEX


Exhibit
Number                             Description
------                             -----------

3.1      Articles of Incorporation (1)

3.2      Bylaws (1)

31.1     Certification of Principal Executive Officer pursuant to Section 302 of
         the Sarbanes-Oxley Act of 2002.

31.2     Certification of Principal Financial Officer pursuant to Section 302 of
         the Sarbanes-Oxley Act of 2002.

32.1     Certification of Principal  Executive and Principal  Financial  Officer
         and pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101      Interactive data files pursuant to Rule 405 of Regulation S-T. (2)

----------
(1)  Incorporated  by reference to the  Registrant's  Registration  Statement on
     Form S-1 (File No. 333-188610), filed with the Commission on May 15, 2013.
(2)  Incorporated  by reference to the  Registrant's  Annual Report on Form 10-K
     (File No. 000-55023), filed with the Commission on June 12, 2015.